CHICAGO—The first drug to hold advanced uveal melanoma in check — doubling progression-free survival — was announced at the 2013 American Society of Clinical Oncology meeting in Chicago. Dr Richard Carvajal from Memorial Sloan-Kettering Cancer Center in New York presented results from a Phase II study with 98 patients randomised to receive an old drug, temozolomide, or selumetinib which inhibits the MEK pathway affected by GNAQ and GNA II gene mutations commonly found in this rare tumour. He discussed findings with Peter Goodwin.
You may also like...
Lowering hematocrit below 45 per cent protects against clotting risk in patients with polycythemia vera — randomized study finding 11 Dec, 2012 Ribociclib Aids First-Line Endocrine Therapy in Premenopausal Advanced Breast Cancer 18 Apr, 2018 ASCO Audio Journal of Oncology – June 15th 2006 14 Jun, 2006 Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer 16 Oct, 2007
- Previous story Audio Journal of Oncology with Oncology Times, June 2013
- Next story Patients with oropharyngeal cancer: no HPV risk to spouses, partners
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014